Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Sees Large Increase in Short Interest

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 55,100 shares, a growth of 2,523.8% from the January 15th total of 2,100 shares. Based on an average daily volume of 171,000 shares, the short-interest ratio is presently 0.3 days.

Enzon Pharmaceuticals Stock Performance

Enzon Pharmaceuticals stock opened at $0.15 on Thursday. The firm has a market capitalization of $11.13 million, a price-to-earnings ratio of 15.02 and a beta of 0.26. Enzon Pharmaceuticals has a fifty-two week low of $0.06 and a fifty-two week high of $0.24. The stock’s fifty day moving average is $0.15 and its two-hundred day moving average is $0.13.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.